Identification of the molecular subclass of breast cancer, the HER-2 amplified form, initiated a revolutionary change in the treatment of this cancer, originally using anti-HER-2 antibodies, later complementing it with small molecular TK inhibitors (33). The gene discussed is ERBB2; the disease is cancer.